Abstract
The disease anthrax is caused by lethal factor1, an enzyme component of the toxin produced by the spore-forming bacterium Bacillus anthracis2. Here we describe substrate molecules for this factor that offer a means for high-throughput screening of potential inhibitors for use in anthrax treatment3. Our assay should help to answer the urgent call for new and specific therapies4 to combat this pathogen after its recent emergence as a terrorist bioweapon.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hanna, P. Curr. Topics Microbiol. Immunol. 225, 13–35 (1998).
Mock, M. & Fouet, A. Annu. Rev. Microbiol. 55, 647–671 (2001).
Chaudry, G. J., Moayeri, M., Liu, S. & Leppla, S. H. Trends Microbiol. 10, 58–62 (2002).
Friedlander, A. M. Nature 414, 160–161 (2001).
Friedlander, A. M. J. Biol. Chem. 261, 7123–7126 (1986).
Duesbery, N. S. et al. Science 280, 734–737 (1998).
Vitale, G. et al. Biochem. Biophys. Res. Commun. 248, 706–711 (1998).
Vitale, G., Bernardi, L., Napolitani, G., Mock, M. & Montecucco, C. Biochem. J. 352, 739–745 (2000).
Pannifer, A. D. et al. Nature 414, 229–233 (2001).
Roques, B. P. Trends Pharmacol. Sci. 21, 475–483 (2000).
Schwarze, S. R., Hruska, K. A. & Dowdy, S. F. Trends Cell Biol. 10, 290–295 (2000).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
brief communications is intended to provide a forum for both brief, topical reports of general scientific interest and technical discussion of recently published material of particular interest to non-specialist readers. Priority will be given to contributions that have fewer than 500 words, 10 references and only one figure. Detailed guidelines are available on Nature's website (http://www.nature.com/nature) or on request from nature@nature.com
Supplementary information
Rights and permissions
About this article
Cite this article
Tonello, F., Seveso, M., Marin, O. et al. Screening inhibitors of anthrax lethal factor. Nature 418, 386 (2002). https://doi.org/10.1038/418386a
Issue date:
DOI: https://doi.org/10.1038/418386a
This article is cited by
-
Effects of metalloprotease anthrax lethal factor on its peptide-based inhibitor R9LF-1
Molecular and Cellular Biochemistry (2015)
-
Structure-based pharmacophore modeling and virtual screening to identify novel inhibitors for anthrax lethal factor
Medicinal Chemistry Research (2014)
-
Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group
Applied Microbiology and Biotechnology (2012)
-
Quantum mechanical/molecular mechanical study of anthrax lethal factor catalysis
Theoretical Chemistry Accounts (2011)
-
The biology and future prospects of antivirulence therapies
Nature Reviews Microbiology (2008)
